Cytovance Biologics has entered into a development and manufacturing agreement with Pamlico Biopharma, an Oklahoma City, OK-based clinical stage biopharma company. Pamlico has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections. Pamlico has contracted Cytovance Biologics as its CMO to develop a production cell line from the protein’s amino acid sequence for GMP manufacture of Phase I material. “With this agree...